Literature DB >> 7781372

Talc slurry pleurodesis. Pleural fluid and histologic analysis.

L Kennedy1, R A Harley, S A Sahn, C Strange.   

Abstract

Although talc slurry pleurodesis is effective for control of malignant pleural effusions and recurrent pneumothorax, the mechanisms of pleurodesis remain incompletely defined. We instilled 70 mg/kg of sterile asbestos-free talc slurry into the pleural space of New Zealand white rabbits and studied the inflammatory response at 1, 2, 3, 7, 15, 30, 60, 90, and 120 days by observing pleural fluid and histologic characteristics. Talc slurry caused mesothelial denudement and an exudative neurotrophilic pleural effusion that resolved after 48 h. A transient mononuclear vasculitis was seen within the lung at 1, 2, and 3 days after instillation. Pleural adhesions were minimal and did not increase in number over time. Talc was found outside of the pleural space in mediastinal lymph nodes (4 of 23 animals examined), kidney (1 of 6), and spleen (4 of 10). The predominant cause of pleurodesis with talc slurry instillation is an acute pleural injury similar to the tetracycline class agents.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7781372     DOI: 10.1378/chest.107.6.1707

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

1.  Experimental validation of talc pleurodesis for carcinomatous pleuritis in an animal model.

Authors:  Yasunori Iwasaki; Shinzo Takamori; Masahiro Mitsuoka; Masaki Kashihara; Tatsuya Nishi; Daigo Murakami; Ryoichi Matsumoto; Hiroharu Mifune; Yuji Tajiri; Yoshito Akagi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-12

2.  Optimal management of malignant pleural effusions (results of CALGB 30102).

Authors:  Todd L Demmy; Lin Gu; Jack E Burkhalter; Eric M Toloza; Thomas A D'Amico; Susan Sutherland; Xiaofei Wang; Laura Archer; Linda J Veit; Leslie Kohman
Journal:  J Natl Compr Canc Netw       Date:  2012-08       Impact factor: 11.908

3.  Transforming growth factor beta2 induced pleurodesis is not inhibited by corticosteroids.

Authors:  Y C Lee; C J Devin; L R Teixeira; J T Rogers; P J Thompson; K B Lane; R W Light
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

4.  Comparison of mitoxantrone and tetracycline as pleural sclerosing agents in rabbits.

Authors:  R W Light; N S Wang; J A Despars; S E Gruer; C Sassoon; F S Vargas
Journal:  Lung       Date:  1996       Impact factor: 2.584

5.  Changes in the pleural cavity by pleurodesis using talc or OK-432: an experimental study.

Authors:  Fumihiko Muta; Shinzo Takamori; Toshihiro Matsuo; Yasunori Iwasaki; Koichi Yoshiyama; Kazuo Shirouzu
Journal:  Surg Today       Date:  2010-12-30       Impact factor: 2.549

6.  Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study.

Authors:  Marta Korsic; Sonja Badovinac; Branka Cucevic; Zoran Janevski
Journal:  Wien Klin Wochenschr       Date:  2015-04-10       Impact factor: 1.704

7.  Transforming growth factor beta(2) (TGF beta(2)) produces effective pleurodesis in sheep with no systemic complications.

Authors:  Y C Lee; K B Lane; R E Parker; D S Ayo; J T Rogers; R W Diters; P J Thompson; R W Light
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

8.  Pancreatitis associated with pleural-mediastinal pseudocyst, panniculitis and polyarthritis.

Authors:  A López; J García-Estañ; C Marras; M Castaño; M J Rojas; C Garre; J Gómez
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

9.  Comparison of side effects of oxytetracycline and talc pleurodesis: an experimental study.

Authors:  Alper Gözübüyük; Berkant Ozpolat; Ali Fuat Ciçek; Hasan Caylak; Orhan Yücel; Kuthan Kavaklı; Sedat Gürkök; Onur Genç
Journal:  J Cardiothorac Surg       Date:  2010-12-13       Impact factor: 1.637

10.  Effectiveness and safety of iodopovidone in an experimental pleurodesis model.

Authors:  Lisete R Teixeira; Francisco S Vargas; Juliana Puka; Milena M P Acencio; Leila Antonangelo; Ricardo M Terra; Francisco M Damico; Fabio G Pitta; Evaldo Marchi
Journal:  Clinics (Sao Paulo)       Date:  2013-04       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.